Plasma Kallikrein Inhibitors in Cardiovascular Disease

2016 ◽  
Vol 24 (3) ◽  
pp. 99-109 ◽  
Author(s):  
Dhaval Kolte ◽  
Zia Shariat-Madar
Keyword(s):  
Cardiovascular Disease ◽  
Plasma Kallikrein ◽  
Kallikrein Inhibitors

scholarly journals Structure-Inhibitory Activity Relationship of Plasmin and Plasma Kallikrein Inhibitors

2001 ◽  
Vol 49 (11) ◽  
pp. 1457-1463 ◽  
Author(s):  
Yuko TSUDA ◽  
Mayako TADA ◽  
Keiko WANAKA ◽  
Utako OKAMOTO ◽  
Akiko HIJIKATA-OKUNOMIYA ◽  
...  
Keyword(s):  
Inhibitory Activity ◽  
Activity Relationship ◽  
Plasma Kallikrein ◽  
Relationship Of ◽  
Kallikrein Inhibitors

The Plasma Kinin-Forming System in Labour

1973 ◽  
Vol 45 (4) ◽  
pp. 429-438
Author(s):  
M. Malofiejew
Keyword(s):  
Pregnant Women ◽  
Human Myometrium ◽  
Plasma Kallikrein ◽  
Second Stage ◽  
Second Stage Of Labour ◽  
Isolated Rat ◽  
Kallikrein Inhibitors ◽  
Plasma Kinin

1. The plasma of non-pregnant women contains practically no kinins and only traces of kallikrein. Treatment of the plasma with kaolin produces additional amounts of kallikrein from prekallikrein and of kinin from kininogen. 2. During the second stage of labour, plasma kallikrein is increased and the amount of kallikrein inhibitors is decreased. The plasma kinin-forming activity is only slightly increased due, apparently, to a fall in plasma kininogen. 3. Plasma kallikrein causes a rise in the contractile tonus of the isolated rat and human myometrium.

scholarly journals Changes in Levels of Plasma Pre-Kallikrein, Kallikrein and Kallikrein Inhibitors During Endotoxin Shock in Dogs

1977 ◽  
Author(s):  
M. J. Gallimore ◽  
A. O. Aasen ◽  
E. Amundsen
Keyword(s):  
Late Phase ◽  
Endotoxin Shock ◽  
Time Dependent ◽  
Plasma Kallikrein ◽  
Kinin System ◽  
E Coli ◽  
Dependent Inhibition ◽  
Kallikrein Kinin System ◽  
Time Dependent Inhibition ◽  
Kallikrein Inhibitors

Plasma protease activity is known to be increased during endotoxin shock and recent studies have indicated that the plasma kallikrein-kinin system becomes activated by circulating endotoxin. Plasma levels of pre-kallikrein kallikrein and kallikrein inhibitors were therefore determined in samples from dogs infused with E. coli endotoxin, using assays with a chromogenic substrate for plasma kallikrein(Chromozyme -PK, Pentapharm, Basle, Switzerland). “Fast-reacting” and “time-dependent” inhibitors of kallikrein were studied using purified human plasma kallikrein. Considerably reduced levels of plasma pre-kallikreiri and increased levels of kallikrein were detected in the late phase of shock and significant reductions in “fast-reacting” and “time-dependent” inhibition of kallikrein was observed. These results show that during endotoxin shock plasma pre-kallikrein becomes activated to kallikrein and indicate that kallikrein inhibitors play an important mediatory role in the pathophysiology of endotoxin shock.

scholarly journals Development of Active Center-Directed Plasmin and Plasma Kallikrein Inhibitors and Studies on the Structure-Inhibitory Activity Relationship.

1993 ◽  
Vol 41 (6) ◽  
pp. 1079-1090 ◽  
Author(s):  
Naoki TENO ◽  
Keiko WANAKA ◽  
Yoshio OKADA ◽  
Hiroaki TAGUCHI ◽  
Utako OKAMOTO ◽  
...  
Keyword(s):  
Active Center ◽  
Inhibitory Activity ◽  
Activity Relationship ◽  
Plasma Kallikrein ◽  
Kallikrein Inhibitors

scholarly journals Structure-Guided Design of Novel, Potent, and Selective Macrocyclic Plasma Kallikrein Inhibitors

2016 ◽  
Vol 8 (2) ◽  
pp. 185-190 ◽  
Author(s):  
Zhe Li ◽  
James Partridge ◽  
Abel Silva-Garcia ◽  
Peter Rademacher ◽  
Andreas Betz ◽  
...  
Keyword(s):  
Plasma Kallikrein ◽  
Kallikrein Inhibitors

scholarly journals Longitudinal Plasma Kallikrein Levels and their Association with the Risk of Cardiovascular Disease Outcomes in Type 1 Diabetes in DCCT/EDIC

2020 ◽  
Author(s):  
Ada Admin ◽  
Miran A Jaffa ◽  
Ionut Bebu ◽  
Deirdre Luttrell ◽  
Barbara H Braffett ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Type 1 Diabetes ◽  
Proportional Hazards ◽  
Cox Proportional Hazards ◽  
Major Adverse Cardiovascular Events ◽  
Plasma Kallikrein ◽  
Cvd Risk ◽  
20 Nm ◽  
Adjusted Model

We determined the relationship between plasma kallikrein and cardiovascular disease (CVD) outcomes as well as major adverse cardiovascular events (MACE) in the DCCT/EDIC-cohort of type 1 diabetes (T1D). Plasma kallikrein levels were measured longitudinally in 693 subjects at DCCT baseline (1983-1989), mid-point of DCCT (1988-1991), end of DCCT (1993), and EDIC years 4-6 (1997-1999), 8-10 (2001-2003), and 11-13 (2004-2006). Cox proportional hazards regression models assessed the association between plasma kallikrein levels and the risk of CVD. In unadjusted models, higher plasma kallikrein levels were associated with higher risk of any CVD during DCCT/EDIC (HR=1.16 per 20 nM higher levels of plasma kallikrein; p=0.0177) as well as over the EDIC-only period (HR=1.22; p=0.0024). The association between plasma kallikrein levels and the risk of any CVD remained significant during the EDIC follow-up after adjustment for age and mean HbA1c (HR=1.20; p=0.0082) and in the fully adjusted model for other CVD risk factors (HR=1.17; p=0.0330). For MACE, higher plasma kallikrein levels were associated with higher risk in unadjusted (HR=1.25; p=0.0145), minimally adjusted (HR=1.23; p=0.0417, and fully adjusted (HR=1.27; p=0.0328) models during EDIC-only. These novel findings indicate that plasma kallikrein level associates with the risk of any CVD and MACE in T1D individuals.

Sign in / Sign up

Export Citation Format

Share Document